Real-World Use, Safety, and Patient Experience of 20% Subcutaneous Immunoglobulin for Primary Immunodeficiency Diseases

CONCLUSION: The CORE study provides real-world evidence of the flexibility, feasibility, safety, and tolerability of Ig20Gly infusions, at mostly weekly intervals, over 1 year in patients with PIDs.TRIAL REGISTRATION: German Clinical Trials Register, DRKS00014562. Registered April 9, 2018, https://drks.de/search/en/trial/DRKS00014562.PMID:37751025 | DOI:10.1007/s12325-023-02649-0

Source: Adv Data - September 26, 2023 Category: Epidemiology Authors: Maria Fasshauer Michael Borte Michaela Bitzenhofer Christine Pausch David Pittrow Michelle Park Andr é Gladiator Peter Jandus Source Type: research